Clinical Trials
17 trialsNCT06110793 2026-05-13
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07096609 2026-04-03
LONGIST
Asan Medical Center
Phase 1/2 Recruiting
NCT07282184 2025-12-18
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Tongji Hospital
Phase 1/2 Recruiting
NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT07149090 2025-11-20
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
Asan Medical Center
Phase 1/2 Recruiting
NCT02562118 2025-09-25
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT05774899 2025-06-17
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06746961 2024-12-24
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Not yet recruiting
NCT05973903 2024-12-04
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Tel Aviv Medical Center
Phase 1/2 Withdrawn
NCT06081907 2024-05-30
Promise
Hunan Province Tumor Hospital
Phase 1/2 Recruiting
NCT06409637 2024-05-10
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT06140576 2023-11-20
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT04443309 2023-03-29
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown